A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy
Completed · Phase 3 · Has a placebo group
Conditions studied: Acute Pain
In brief
The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a bunionectomy.
Key facts
- Study ID
- NCT06423703
- Run by
- Tris Pharma, Inc.
- People needed
- 240
- Starts
- 2024-07-18
- Expected to finish
- 2025-01-31
- Last updated by the study team
- 2026-01-26
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- ALLEVIATE 2 Site 001108 — Sheffield, Alabama, United States
- ALLEVIATE 2 Site 001106 — Little Rock, Arkansas, United States
- ALLEVIATE 2 Site 001103 — Tampa, Florida, United States
- ALLEVIATE 2 Site 001102 — Atlanta, Georgia, United States
- ALLEVIATE 2 Site 001107 — Overland Park, Kansas, United States
- ALLEVIATE 2 Site 001105 — Pasadena, Maryland, United States
- Alleviate 2 001113 — Houston, Texas, United States
- ALLEVIATE 2 Site 001104 — McAllen, Texas, United States
- ALLEVIATE 2 Site 001111 — San Antonio, Texas, United States
- ALLEVIATE 2 Site 001101 — Salt Lake City, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.